In the network meta-analysis, XHTuC (capecitabine + trastuzumab + tucatinib) ranked first in SUCRA for ORR and second in SUCRA for PFS and OS, showing an excellent effect in striking HER2-overexpressing tumor cells among second-line therapies. Here, ERBB2 is linked to neoplasm.